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Background: The immunologic environment during HIV/M. tuberculosis co-infection is characterized by cytokine and
chemokine irregularities that have been shown to increase immune activation, viral replication, and T cell dysfunction.
Methods: We analysed ex vivo plasma samples from 17 HIV negative and 16 HIV pulmonary tuberculosis co infected
cases using Luminex assay to see impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary
tuberculosis patients before and after anti Tuberculosis treatment.
Results: The median plasma level of IFN-γ, IL-4, MCP-3, MIP-1β and IP-10 was significantly different (P < 0.05) before and
after treatment in HIV negative TB patients but not in HIV positive TB patients. There was no significant difference
between HIV positive and HIV negative TB patients (P > 0.05) in the plasma level of any of the cytokines or chemokines
before treatment and anti TB treatment did not change the level of any of the measured cytokines in HIV positive
tuberculosis patients. The ratio of IFN-γ/IL−10 and IFN-γ/IL−4 showed a significant increase after treatment in HIV
negative TB cases but not in HIV positive TB cases which might indicate prolonged impairment of immune response
to TB in HIV positive TB patients as compared to HIV negative tuberculosis patients.
Conclusions: HIV positive and HIV negative Tuberculosis patients display similar plasma cytokine and chemokine
pattern. However, anti TB treatment significantly improves the Th1 cytokines and level of chemokines but does not
restore the immune response in HIV positive individuals.
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Tuberculosis (TB) and HIV/AIDS have proven to be a
deadly and mutually reinforcing combination. In the ab-
sence of anti-retroviral therapy, HIV-infected individuals
with latent tuberculosis infection have 5–10% annual
risk of TB disease in contrast to 10% during life-time in
HIV negative individuals [1]. A high risk of TB has been
shown in early stages of the HIV disease, even in the
presence of normal CD4+ cell counts [2]. The factors
contributing to this increased risk are not clear, but may in-
clude a compromised response by CD4+ T cells, defective* Correspondence: adane_mihret@yahoo.com
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unless otherwise stated.innate immunity and/or other elements of the host
response against Mycobacterium tuberculosis [3,4].
Understanding what constitutes protective immunity
to TB is critical for development of new diagnostics,
treatment protocols and identifying vaccine candidates.
In order to understand the immune profile of TB disease
and infection, a number of parameters need to be consid-
ered. These include the HIV status with the majority of
diagnostic tests not applicable for HIV positive patients.
The cytokine response to TB antigens has been studied
extensively but results have varied possibly due to differ-
ences in the genetic background of the study population,
the type and length of antigen stimulation, the experimental
protocol used and the sample type [5-7].
Although the pathogenesis of HIV-tuberculosis co-
infection is not well understood, the immunologic envir-
onment during M. tuberculosis infection is characterizedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lieved to increase T cell activation, enhance HIV replica-
tion and result in a dysfunctional immune response
[8-12]. A reduction of Immune activation and HIV viral
load after treatment of opportunistic infections other
than TB is well recognized. Treatment of TB on the
level of cytokines and chemokines among HIV-infected
adults with tuberculosis is poorly characterized and ef-
fect of TB treatment on viral load and plasma cytokine
response have been contradictory where some studies
shown an increase pro-inflammatory immune response
and decrease HIV viral load in response to TB therapy
[9,13] while in other studies not [14-16]. Some studies
also shown decrease in immune activation with no effect
on viral load [17].
We recently described in a cross-sectional study that
anti TB treatment changed the plasma level of cytokines
and chemokines in HIV negative TB patients [18]. Here
we used the same panel of cytokines to explore the hy-
pothesis that there is a difference between the immune
response before and after anti TB treatment in TB pa-
tients who are HIV positive compared to those who are
HIV negative. We used direct unstimulated plasma sam-
ples assuming the sample represents the systemic activa-
tion in vivo and reflects the systemic immune response
to see the immune response in TB cases who are HIV
positive and HIV negative and for monitoring anti TB
treatment outcome in both groups.
Materials and methods
Study subjects
We obtained ethical clearance from AHRI/ALERT
Ethics Review Committee (P015/10) and National Re-
search Ethics Review Committee (NRERC) (3.10/17/
10). The participants voluntarily agreed to participate
in the study and signed an informed consent form. In
this study 33 individuals with active TB disease (17
HIV negative and 16 HIV positive) were recruited
and followed from 4 health centers in Addis Ababa,
Ethiopia. Diagnosis for TB was made by smear micros-
copy for AFB. All TB cases were new smear positive
pulmonary TB cases and treated for 8 months with
2RHZE/6RE under DOTS and treatment adherence
had been assessed by health extension workers. Effect-
ive anti TB therapy had been checked and confirmed
by negative sputum acid fast bacillus at the end of the
treatment.
All sputum samples from TB cases were cultured for
mycobacteria. The presence of HIV infection was tested
using rapid tests (Stat pack, KHP and Unigold as a tie
breaker) as per the national guideline. In Ethiopia all pa-
tients attending TB clinics screened for sexually trans-
mitted infections including HIV using a set of simple
questions. As soon as HIV is identified in a TB patient,the patient is enrolled to HIV chronic care. The HIV
care is delivered at the TB clinic for the duration of TB
treatment or the patient may be referred to an HIV
Chronic Care/ART clinic. The decision to initiate ART
to TB patients is made by a trained clinician based on
their CD 4 count. The first priority for HIV-positive TB
patients is to initiate TB treatment, followed by cotri-
moxazole and ART. HIV positive TB patients with pro-
found immune-suppression (CD4 counts less than 50
cells cells/mm3) received ART immediately within the
first 2 weeks of initiating TB treatment. Otherwise, tim-
ing of ART initiation is up to clinical judgment based on
other signs of immunodeficiency indicating progression
of HIV disease [19].
Multiplex analysis
Blood sample was collected with heparin tubes twice at
recruitment and after completion of anti TB treatment.
Plasma was separated by centrifugation at 1000 rpm for
5 min and stored at −20 until the multiplex analysis was
performed.
We used a 17plex kit (Epidermal Growth Factor (EGF),
FRACTALKINE, Granulocyte Macrophage Colony Stimu-
lating Factor (GM CSF), IFN-γ, IL-1, IL 10, IL-12, IL-17,
IL-4, IL-7, IL-9, IFN-γ inducible protein (IP-10 /CXCL-
10), Macrophage Chemo-attractant Protein 1 (MCP- 1/
CXCL), MCP-3, Monocyte Inflammatory Protein 1 beta
(MIP-1β), TNF and VEGF) from Millipore, Germany
and multicytokine analysis was done using Luminex
(Millipore, Germany) technology. The assays were per-
formed according to the supplier’s instructions. Briefly, fol-
lowing pre wetting of plates, 50 μl of precombined beads
from all the 17 individual cytokines or chemokines was
added and washed twice after 1 hr incubation at room
temperature. Plasma samples (25 μl) were diluted 1:1 with
the kit serum matrix and added to the plate. The plate was
shaken for 30 sec at 1000 RPM and then incubated for 1 hr
on plate shaker (300 RPM) at room temperature. The plates
were washed twice and 25 ul of detection antibody was
added per well and incubated for 1 hr again on a plate
shaker. Fifty micro liter of streptavidin-PE conjugate was
added per well and incubated for 30 min at room
temperature. Finally, the plate was washed 3 times and
150 μl of sheath fluid was added to each well and then the
plate was read by Luminex machine (Millipore, Germany).
Data was analysed using Luminex 100 IS software version
2.3.182. The Human Cytokine Quality Controls 1 and 2
and Assay buffer included in the kit were used as low and
high concentration quality controls and background (Blank)
respectively. Six non zero standard points ranging from
3.2 pg/ml to 10 000 pg/ml were assayed in duplicate to gen-
erate standard curve and the correlation coefficient (R2)
was calculated in each experiment to see the linearity of the
standard curve.
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The data were analyzed using Graph pad prism software,
version 4.0. Data were log transformed to normalize their
distribution. Nonparametric Mann–Whitney U tests were
performed to check for the significance of the observed
differences in each parameter in HIV positive and HIV
negative TB cases.
Results
We enrolled 33 subjects with active tuberculosis of
which 16 were HIV positive and all were ART naïve with
a mean CD4 count of 310 ± 23.9 cells/μL. The mean
age of HIV positive TB patients and HIV negative TB
patients was 29.6 ± 1.3 and 31.8 ± 1.2 respectively and
48.5% of the participants were females.
Effect of HIV on plasma level of cytokines and
chemokines on TB patients
We found that the median plasma level of the cyto-
kines and chemokines measured was not affected by
HIV status although the HIV positive TB patients have
a slightly higher level of most of the cytokines and
chemokines (Figure 1).Figure 1 Plasma cytokine and chemokine level in HIV negative and HIV p
(n = 16) and HIV negative TB cases (n = 17) were assessed by multiplex cytokine
(IFN-γ, IL 12(p40), and TNF) C) Anti-inflammatory cytokines (IL-10 and IL-4) and D
lines indicate median of HIV negative (filled circles) and HIV positive TB cases (o
with p-values indicating significant differences after transformation of data to LoImpact of anti TB treatment on plasma level of cytokines
and chemokines
We also measured the plasma level of the cytokines and
chemokines after 8 month of effective anti-TB therapy
to see if any of these cytokines and chemokines showed
a difference among HIV positive and HIV negative TB
patients as a result of treatment. We found that the
median level of IFN-γ, IL-4, IP-10, MCP-3 and MIP-1β
were statistically different (p < 0.05) after treatment in
HIV negative TB patients but not in HIV positive TB
patients (p > 0.05) (Figure 2). The median plasma level
of IL-4 and IP-10 was significantly decreased whereas
the level of IFN-γ, MCP-3 and MIP-1β significantly in-
creased after treatment in HIV negative TB patients.
We also analysed the ratio of Th1 (IFN-γ and IL-12
(p40)) and Th2 (IL-4 and IL-10) cytokines before and
after treatment. None of the ratios of IFN-γ/IL−4, IFN-
γ/IL−10, IL-12(p40)/IL-4 and IL-12(p40)/IL-10 were sig-
nificantly different between TB patients who are HIV
positive or HIV negative (Figure 2). Whereas the plasma
concentration of IFN-γ/IL−4 and IFN-γ//IL−10 was sig-
nificantly higher (p < 0.05) in HIV negative TB patients
than HIV positive TB patients after treatment (Figure 3).ositive TB cases. Unstimulated plasma samples from HIV positive TB cases
analysis. A) Growth factors (EGF and VEGF) B) Pro-inflammatory cytokines
) Chemokines (IP-10, MCP-1, MCP-3, MIP-1β and fractalkine). Horizontal
pen circles). Data were analysed using nonparametric Mann–Whitney test
g10 values.
Figure 2 Unstimulated plasma samples from HIV negative TB cases before treatment, after treatment (n = 17) and HIV positive TB
cases before treatment and after treatment (n = 16) was assessed by multiplex cytokine analysis. A) Growth factors (EGF and VEGF) B)
Pro-inflammatory cytokines (IFN-γ, IL 12(p40), and TNF) C) Anti-inflammatory cytokines (IL-10 and IL-4) and D) Chemokines (IP-10, MCP-1, MCP-3,
MIP-1β and fractalkine). Horizontal lines indicate median of HIV negative TB cases before treatment (filled circles), HIV negative TB cases after
treatment (filled triangle), HIV positive TB cases before treatment (filled diamond) and HIV positive TB cases after treatment (filled inverted triangle).
Data were analysed using nonparametric Mann–Whitney test with p-values indicating significant differences after transformation of data to Log10
values *p < 0.05.
Mihret et al. BMC Infectious Diseases 2014, 14:125 Page 4 of 7
http://www.biomedcentral.com/1471-2334/14/125Discussion
This study identifies differences in cytokine levels in TB
patients with and without HIV and before and after anti
TB treatment that may potentially plays a role in the
protection or development of TB. We measured the
plasma level of pro-inflammatory cytokines (IFN-γ, IL
12(p40), and TNF), Anti-inflammatory cytokines (IL-10
and IL-4), Growth factors (EGF and VEGF) and Chemo-
kines (IP-10, MCP-1, MCP-3, MIP-1β and fractalkine).
The main findings of this study were: (a) HIV co-
infection does not seem to affect the median plasma
level of any of the cytokine/chemokine in TB patients
and there was no statistically significant difference be-
tween HIV positive and HIV negative TB patients; (b)
The plasma level of IFN-γ, IL-4, IP-10, MCP-3 and MIP-
1β significantly changed after completion of anti-TBtreatment in HIV negative TB patients whereas in HIV
positive TB patients none of the cytokines and chemo-
kines showed significant difference after anti TB treat-
ment; (c) The ratio of IFN-γ/IL−4 and IFN-γ/IL−10
were statistically different (p < 0.05) in HIV negative TB
patients after treatment; and (d) The ratio of Th1/Th2
cytokines in HIV positive TB patients was not changed
after treatment and it was significantly lower than HIV
negative tuberculosis cases after anti TB treatment.
At baseline, TB + HIV + individuals displayed a similar
plasma cytokine level when compared to TB +HIV- in-
dividuals. This could be due to both tuberculosis and
HIV infection inducing immune activation in a similar
pattern or due to the nature of HIV positive participants
in this study where majority of them were at less ad-
vanced HIV infection stage as confirmed by their CD4
Figure 3 Th1/Th2 ratios of cytokines of TB cases after anti TB treatment. Box plots are shown with the horizontal line indicating median
levels of TB cases and the lower and upper edge of each box indicate the 25th and 75th percentiles, respectively. Ratio of Th1/Th2 cytokines (IL-12/IL-10,
IL-12/IL-4, IFN-γ/IL-10 and IFN-γ/IL-4) of TB patients who are HIV negative before treatment (white bars), TB patients who are HIV positive
before treatment (Dotted bars), TB patients who are HIV negative after treatment (grey bars) and TB patients who are HIV positive after
treatment negative (crossed bars). Data were analysed using nonparametric Mann–Whitney test with p-values indicating significant differences
after transformation of data to Log10 values.
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tients have a similar plasma cytokine and chemokine
level with healthy household contacts after completion
of anti TB treatment [18]. Different studies have shown
that both tuberculosis and HIV infection can inhibit T
cell effector functions, such as production of IFN-γ and
interleukin-2, and co-infection is associated with more pro-
found suppression of type-1 cytokine responses [10,20,21].
Longitudinal assessment of the plasma cytokine profile
showed that out of the 17 cytokines measured, the
plasma level of IFN-γ, IL-4, IP-10, MCP-3 and MIP-1β
significantly changed after completion of anti-TB treat-
ment in HIV negative TB patients whereas in HIV posi-
tive TB patients none of the cytokines and chemokines
showed significant difference after anti TB treatment.
The median plasma level of IL-4 and IP-10 was signifi-
cantly decreased whereas the level of IFN-γ, MCP-3
and MIP-1β significantly increased after treatment. Be-
cause IFN-γ is a pro-inflammatory and IL-4 is an anti-
inflammatory cytokine, it is reasonable to suggest that
the increased concentration of IFN-γ and the reduced
concentration of IL-4 might be due to the clearance of
the actively multiplying bacteria and resolution of the
disease following effective anti-tuberculosis treatment.
The decrement of IP-10 and increment of MCP-1 and
MIP-1β after treatment has been also reported by other
studies [22-24]. IP-10 is involved in trafficking mono-
cytes and activated Th1 cells to inflamed foci and the
reduction of this chemokine could be due to resolution
of inflammation as a result of anti TB treatment. The
increased concentration of MCP-1 and MIP-1b is sig-
nificant because of the key role these two cytokines
play in the control of infection by attracting cells to
the granuloma. In TB + HIV + patients the level of allof the cytokines and chemokines measured was not
changed and this could be due to the ongoing inflam-
matory immune response.
The ratio of Th1/Th2 in HIV + and HIV- TB patients
showed no difference before treatment whereas the ratio
of IFN-γ/IL−4 and IFN-γ/IL−10 showed a significant
difference before and after treatment in HIV negative TB
cases where as none of the Th1/Th2 cytokines ratio
showed a significant difference after treatment in HIV
positive TB cases. The ratio of Th1/Th2 cytokines in
HIV positive TB patients was lower than HIV negative
TB cases. The higher level of IFN-γ/IL−4 and IFN-γ/IL−10
in HIV negative TB cases is expected where a Th1 type im-
mune response dominates after clearance of the actively
multiplying bacteria and resolution of the disease by the
anti-tuberculosis treatment. In HIV positive TB patients
anti TB treatment did not change the level of circulatory
cytokines. It remains unclear whether tuberculosis treat-
ment has a significant impact on other markers of HIV
disease progression, such as T cell counts and changes
in T cell subsets. Some studies reported that tubercu-
losis treatment increased CD4 T cell count among per-
sons with HIV-tuberculosis co infection [13,25] whereas
others indicated anti TB treatment didn’t show any
change in absolute CD4 T cell count or restoration of
the naive T cell population [26].
The lower ratio of IFN-γ/IL-4 and IFN-γ/IL−10 after
anti TB treatment in HIV positive patients could be due
to immune exhaustion by HIV co-infection with a possi-
bility of future development of TB in HIV-infected indi-
viduals through down-regulation of IFN-γ and IL-12 and
up-regulation of IL-4 and IL-10. The higher level of IL-
10 and IL-4 in co-infected TB patients might be due to
the immune exhaustion by HIV where the HIV-specific
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IL-4 and IL-10. Previous studies suggested that the level
of IL-10 is elevated in chronic HIV disease [27]. More-
over, lower IL-12 production by PBMC in response to
TB antigens and lower levels of both Th1 and Th2 cyto-
kines by PBMC correlate with increased susceptibility
and development of TB in HIV-infected individuals and
may be responsible for their increased susceptibility [28].
Moreover, a reduced ratio of IFN-γ/IL-4 might indicate
increased disease severity in HIV positive TB patients as
lower ratio of IFN-γ/IL-10 has been found to relate with
increased disease severity in pulmonary and extrapul-
monary TB [29].
The findings in this study however need further de-
tailed analysis including (i) larger sample size, (ii) viral
load and (iii) CD 4 count for HIV negative TB cases and
after anti TB treatment for both groups to validate and
confirm that the observed dysregulation of cytokine and
chemokine production are indeed associated with in-
creased susceptibility.Conclusions
HIV positive and HIV negative Tuberculosis patients
display similar plasma cytokine and chemokine pattern.
However, anti TB treatment significantly improves the
Th1 cytokines and level of chemokines but does not re-
store the immune response in HIV positive individuals.
This finding may suggest that in dually infected subjects,
the HIV-related changes dominate the overall immuno-
logical picture and leads to dysregulation of cytokine
and chemokine production.
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